Exact Sciences
Exact Sciences Stock Spikes After Primary Care Sales Team Nearly Doubles
In notes to investors, analysts said the move would likely drive higher sales of the company's colorectal cancer test, Cologuard.
Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients
The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the US and Canada.
Exact Sciences' Oncotype DX Breast Recurrence Score Assay Receives Japanese Regulatory Approval
The test helps guide treatment and provides risk of distant recurrence in patients with HR-positive, HER2-negative early-stage breast cancer.
Exact Sciences Q2 Revenues Rise 62 Percent
The company said screening revenues in Q2, from Cologuard tests and Biomatrica products, doubled year over year.
The company hopes to complete the trial in early 2022 and submit data to the FDA for approval of its assay, which could compete with Exact Sciences' Cologuard.
May 5, 2021
Jan 11, 2021